SLSNConsumer Defensive · Household & Personal ProductsTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 12 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Solesence, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (93): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (6): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SLSN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SLSN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Nov 2026, Solesence, Inc. returned −53.6% against +12.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 8% of US stocks
Cheaper than 64% of US stocks
Cheaper than 19% of US stocks
Cheaper than 96% of US stocks
Higher than 10% of US stocks
Higher than 19% of US stocks
Higher than 35% of US stocks
Higher than 28% of US stocks
Higher than 23% of US stocks
Higher than 32% of US stocks
Higher than 36% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Solesence, Inc. has a market value of $64.3M and an enterprise value of $86.0M.
Revenue in the twelve months to 30 June 2026: $55.4M. The latest quarter shrank 24.7% year on year.
Net income over the same four quarters: −$1.9M, a −3.4% net margin.
Diluted earnings per share, trailing twelve months: −$0.03.
Free cash flow in the twelve months to 30 June 2026: −$849K.
Trailing P/E: 88.6×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Solesence, Inc. employs 115 people — $481K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Solesence, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The provided text identifies a Seeking Alpha transcript of Solesence, Inc.’s Q3 2026 earnings call but includes no details from the call.
Why it matters — SLSN watchers may note the earnings-call transcript, though the excerpt provides no financial or operational information.
Solésence reported third-quarter 2026 revenue of $20.2 million, up 38% year over year, and net income of $3.7 million, the highest in the company’s history. The company said it would host a conference call at 4:00 p.m. CT (5:00 p.m. ET) that day.
Why it matters — The results provide SLSN watchers with an update on quarterly revenue growth and record net income.
Solésence announced that it will report its third-quarter 2026 financial results after market close on November 12, 2026. The company will host a conference call and webcast that day.
Why it matters — SLSN watchers can note the date when the company is scheduled to release results and discuss them.
Solesence reported break-even earnings for the second quarter, though results were pressured by higher operating expenses. Improving production efficiency and expectations for a stronger second half were cited as favorable factors.
Why it matters — SLSN watchers would care because the company's ability to manage rising costs while showing improved production efficiency signals how it may fare in the second half of the year.
Solesence, Inc. published the transcript of its Q2 2026 earnings call. The item, sourced from Seeking Alpha, is a record of the company's quarterly earnings presentation.
Why it matters — SLSN watchers would look to this transcript for direct commentary from company leadership on its second-quarter 2026 results and outlook.
As at 12 Nov 2026, Solesence, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (93 of 100).
No analyst covering Solesence, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLSN are extrapolating price history, which says nothing about the business.
Solesence, Inc. returned -53.6% over the 12 months to 12 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Solesence Inc. is a science-driven healthcare and personal care company focused on beauty and life science applications.
The most recent item we track (Seeking Alpha, 13 Nov 2026): "Solesence, Inc. (SLSN) Q3 2026 Earnings Call Transcript". The provided text identifies a Seeking Alpha transcript of Solesence, Inc.’s Q3 2026 earnings call but includes no details from the call.
Solesence Inc. is a science-driven healthcare and personal care company focused on beauty and life science applications. It develops and manufactures engineered materials, formulation technologies, and finished products centered on mineral-based skin health. The company’s offerings include surface-engineered zinc oxide and titanium dioxide ingredients, proprietary active ingredients for UV protection, and fully formulated skincare and color cosmetics products such as sunscreens and daily care items. Solesence also provides commercial manufacturing and formulation development services, supporting brands that seek mineral-based solutions with improved transparency, wearability, and aesthetic performance. Based in Romeoville, Illinois, Solesence serves a range of consumer and professional markets across skincare, cosmetics, and related life science uses.
CEO Mr. Kevin Cureton · 115 employees · United States · https://solesence.com
